Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
View in:
PubMed
subject areas
Adult
Adult
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Autoantibodies
Autoantibodies
Double-Blind Method
Double-Blind Method
Drug Administration Schedule
Drug Administration Schedule
Drug Therapy, Combination
Drug Therapy, Combination
Female
Female
Humans
Humans
Immunosuppressive Agents
Immunosuppressive Agents
Longitudinal Studies
Longitudinal Studies
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Male
Male
Middle Aged
Middle Aged
Severity of Illness Index
Severity of Illness Index
Treatment Outcome
Treatment Outcome
authors with profiles
Joan Merrill